• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The promises and potential pitfalls of pharmacokinetic model-based dosing in cellular therapy.

作者信息

Scordo Michael

机构信息

Adult Bone Marrow Transplant Service, Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.

Department of Medicine, Weill Cornell Medical College, New York, NY.

出版信息

Blood Adv. 2024 Dec 10;8(23):6015-6016. doi: 10.1182/bloodadvances.2024012688.

DOI:10.1182/bloodadvances.2024012688
PMID:39368808
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11635718/
Abstract
摘要

相似文献

1
The promises and potential pitfalls of pharmacokinetic model-based dosing in cellular therapy.细胞治疗中基于药代动力学模型给药的前景与潜在风险。
Blood Adv. 2024 Dec 10;8(23):6015-6016. doi: 10.1182/bloodadvances.2024012688.
2
Population pharmacokinetic modelling and estimation of dosing strategy for NXY-059, a nitrone being developed for stroke.用于治疗中风的硝酮NXY-059的群体药代动力学建模及给药策略估算
Clin Pharmacokinet. 2005;44(8):863-78. doi: 10.2165/00003088-200544080-00007.
3
Physiologically-based pharmacokinetic modeling for single and multiple dosing regimens of ceftriaxone in healthy and chronic kidney disease populations: a tool for model-informed precision dosing.基于生理的头孢曲松在健康人群和慢性肾病患者中单剂量和多剂量给药方案的药代动力学建模：一种模型指导精准给药的工具。
Front Pharmacol. 2023 Jul 20;14:1200828. doi: 10.3389/fphar.2023.1200828. eCollection 2023.
4
Lidocaine (lignocaine) dosing regimen based upon a population pharmacokinetic model for preterm and term neonates with seizures.基于人群药代动力学模型的早产儿和足月儿癫痫发作时利多卡因（赛罗卡因）给药方案。
Clin Pharmacokinet. 2011 Jul;50(7):461-9. doi: 10.2165/11589160-000000000-00000.
5
Pharmacogenetics of immunosuppressants: progress, pitfalls and promises.免疫抑制剂的药物遗传学：进展、困境与前景。
Am J Transplant. 2008 Jul;8(7):1374-83. doi: 10.1111/j.1600-6143.2008.02263.x.
6
Model-Informed Precision Dosing of Tacrolimus: A Systematic Review of Population Pharmacokinetic Models and a Benchmark Study of Software Tools.基于模型的他克莫司精准给药：群体药动学模型的系统评价和软件工具的基准研究。
Clin Pharmacokinet. 2024 Oct;63(10):1407-1421. doi: 10.1007/s40262-024-01414-y. Epub 2024 Sep 20.
7
Anti-sense oligodeoxynucleotides--promises and pitfalls.反义寡脱氧核苷酸——前景与问题
Leukemia. 1992 Oct;6(10):967-74.
8
Nevirapine exposure with WHO pediatric weight band dosing: enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience.奈韦拉平暴露与世界卫生组织儿科体重带剂量：基于广泛的国际药代动力学经验预测的增强治疗浓度。
Antimicrob Agents Chemother. 2012 Oct;56(10):5374-80. doi: 10.1128/AAC.00842-12. Epub 2012 Aug 6.
9
Drug dosing optimization in critically ill children under continuous renal replacement therapy: from basic concepts to the bedside model informed precision dosing.持续肾脏替代治疗下危重症儿童的药物剂量优化：从基本概念到床边模型指导的精准给药
Expert Opin Drug Metab Toxicol. 2025 Jan-Feb;21(2):173-190. doi: 10.1080/17425255.2024.2422875. Epub 2024 Nov 4.
10
Population Pharmacokinetics and Optimal Sampling Strategy for Model-Based Precision Dosing of Melphalan in Patients Undergoing Hematopoietic Stem Cell Transplantation.群体药代动力学与基于模型的精准剂量给药用于接受造血干细胞移植患者的美法仑优化采样策略。
Clin Pharmacokinet. 2018 May;57(5):625-636. doi: 10.1007/s40262-017-0581-x.

本文引用的文献

1
Is estimated exposure an accurate surrogate for measured fludarabine levels in patients with CAR T-cell therapy?在接受嵌合抗原受体T细胞（CAR T）治疗的患者中，估计暴露量能否准确替代实测氟达拉滨水平？
Blood Adv. 2024 May 14;8(9):2130-2132. doi: 10.1182/bloodadvances.2023011433.
2
Chimeric antigen receptor T-cell therapy and fludarabine: precision dosing imperatives.嵌合抗原受体T细胞疗法与氟达拉滨：精准给药的必要性。
Blood Adv. 2024 Feb 13;8(3):797-798. doi: 10.1182/bloodadvances.2023012068.
3
Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma.确定阿基仑赛治疗侵袭性 B 细胞非霍奇金淋巴瘤后改善结局的最佳氟达拉滨暴露量。
Blood Adv. 2023 Sep 26;7(18):5579-5585. doi: 10.1182/bloodadvances.2023010302.
4
Fludarabine exposure in the conditioning prior to allogeneic hematopoietic cell transplantation predicts outcomes.在异基因造血细胞移植前的预处理中，氟达拉滨的暴露情况可预测结果。
Blood Adv. 2019 Jul 23;3(14):2179-2187. doi: 10.1182/bloodadvances.2018029421.
5
Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement.《协调白消安血浆暴露单位（BPEU）：社区发起的共识声明》。
Biol Blood Marrow Transplant. 2019 Sep;25(9):1890-1897. doi: 10.1016/j.bbmt.2019.05.021. Epub 2019 May 25.
6
Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation.异基因造血细胞移植预处理儿童和成人氟达拉滨的群体药代动力学。
Clin Pharmacokinet. 2019 May;58(5):627-637. doi: 10.1007/s40262-018-0715-9.
7
Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis.白消安暴露与儿童及青年造血细胞移植后的生存及毒性的关联：一项多中心回顾性队列分析
Lancet Haematol. 2016 Nov;3(11):e526-e536. doi: 10.1016/S2352-3026(16)30114-4. Epub 2016 Oct 13.
8
Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee.基于白消安预处理方案的个体化：来自美国血液和骨髓移植学会实践指南委员会的考量
Biol Blood Marrow Transplant. 2016 Nov;22(11):1915-1925. doi: 10.1016/j.bbmt.2016.07.013. Epub 2016 Jul 29.